Akmus Drugs and Pharmaceutical Limited, based in Delhi, made a groundbreaking announcement on March 16 regarding the development of a new drug for sickle cell disease. This drug marks a significant milestone as the country’s first indigenous, room temperature stable medication for sickle cell disease, offered at a mere 1% of the global price.
The pharmaceutical company aims to provide the government with this innovative medicine at a cost of less than ₹600, making it accessible to a wider population. Union Health Minister Mansukh Mandaviya lauded the initiative, highlighting its potential to combat sickle cell disease and contribute to India’s public health goals.
Sickle cell disease is a hereditary blood disorder that profoundly impacts the lives of affected individuals. With the introduction of this novel drug, patients battling the disease can expect a more accessible and affordable treatment option tailored to their specific needs.
The newly developed oral suspension of Hydroxyurea, designed to remain stable at room temperature, represents a significant advancement in the management of sickle cell disease. This formulation caters to patients across all age groups and ensures precise dosage administration through oral syringes.
Akmus Pharmaceuticals aims to revolutionize the treatment landscape for sickle cell disease by offering an alternative to the costly imported medication. While the current global brand of hydroxyurea solution commands a hefty price tag of approximately ₹77,000 and necessitates storage at specific temperatures, Akmus’s solution promises affordability and convenience without compromising on efficacy.
This initiative underscores the company’s commitment to addressing critical healthcare needs and promoting accessibility to essential medications. As Akmus Pharmaceuticals continues its efforts to make healthcare more affordable and inclusive, the unveiling of this innovative drug marks a significant step forward in the fight against sickle cell disease in India.
